| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 23.31 | 0.35 (+1.52%) | 15.11 - 27.98 | 57.9 thousand |
Market data as of 3:59PM 06/18/13. Quotes are delayed by at least 15 min.
| Open | 23.06 |
|---|---|
| Previous Close | 22.96 |
| Day's Range | 23.01 - 23.50 |
| Market Cap | 338.0M |
| Avg Volume (10 Day) | 61.7K |
| Price/Earnings (Trailing 12 Mo.) | 25.2x |
| Earnings Per Share (Trailing 12 Mo.) | 0.91 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Pass |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Pass |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Pass |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
SurModics to Present at the Jefferies Global Healthcare Conference
Business Wire - Tuesday 05/21/2013 8:00 AM ET
| SRDX | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -6.58% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | 3.97% | |
| Price/Sales | 6.02 |
| Company | Last | Change |
|---|---|---|
| Accelerate Diagnostics Inc | 8.60 | 0.00% |
| Trinity Biotech PLC | 17.15 | 0.00% |
| AMAG Pharmaceuticals Inc | 20.73 | 0.00% |
| Nymox Pharmaceutical Corp | 5.35 | +2.69% |
| Atossa Genetics Inc | 4.69 | 0.00% |
Data is delayed by at least 15 min.